We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-0.09%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.54B
AUM Growth
-$145M
(-3.1%)
Cap. Flow
-$1.24B
Cap. Flow
% of AUM
-27.38%
Top 10 Holdings %
Top 10 Hldgs %
54.9%
Holding
112
New
14
Increased
17
Reduced
7
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bio-Rad Laboratories Class A
BIO
|
+$67.1M |
| 2 |
Surgery Partners
SGRY
|
+$52.5M |
| 3 |
Integra LifeSciences
IART
|
+$47.4M |
| 4 |
Centene
CNC
|
+$42.6M |
| 5 |
AdaptHealth
AHCO
|
+$30.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMED
Amedisys
AMED
|
+$164M |
| 2 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
+$36.8M |
| 3 |
NewAmsterdam Pharma
NAMS
|
+$30.1M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$28.5M |
| 5 |
Cogent Biosciences
COGT
|
+$27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.01% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NUVL
1
DELISTED
Nuvalent
NUVL
| $919M | 20.25% |
19,991,024
| – | – |
|
2
Viatris
VTRS
$20.1B
| $196M | 4.32% |
19,863,485
+2,160,001
| +12% | +$22.5M |
|
|
3
Centene
CNC
$32.8B
| $137M | 3.02% |
1,990,000
+641,000
| +48% | +$42.6M |
|
4
Neurocrine Biosciences
NBIX
$17.2B
| $136M | 3% |
1,209,714
| – | – |
|
|
5
AdaptHealth
AHCO
$1.49B
| $124M | 2.73% |
13,607,940
+2,513,026
| +23% | +$30.1M |
|
|
ACH
6
Accendra Health
ACH
$266M
| $104M | 2.29% |
6,435,000
+1,690,000
| +36% | +$30M |
|
|
CPRX
7
DELISTED
Catalyst Pharmaceutical
CPRX
| $95.8M | 2.11% |
8,192,000
| – | – |
|
|
MRUS
8
DELISTED
Merus
MRUS
| $91.4M | 2.01% |
3,876,938
+845,000
| +28% | +$20.5M |
|
|
DCPH
9
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $87.7M | 1.93% |
6,897,606
+190,580
| +3% | +$2.63M |
|
10
Larimar Therapeutics
LRMR
$384M
| $66.9M | 1.47% |
16,941,357
| – | – |
|
|
11
Bio-Rad Laboratories Class A
BIO
$8.15B
| $62.4M | 1.37% |
+173,947
| New | +$67.1M |
|
12
IDEAYA Biosciences
IDYA
$3.47B
| $61.2M | 1.35% |
2,268,628
| – | – |
|
|
EHAB
13
DELISTED
Enhabit
EHAB
| $56.2M | 1.24% |
4,997,746
+187,943
| +4% | +$2.37M |
|
|
HLVX
14
DELISTED
HilleVax
HLVX
| $53.9M | 1.19% |
4,004,231
+675,000
| +20% | +$9.5M |
|
15
Brookdale Senior Living
BKD
$3.58B
| $52.5M | 1.16% |
12,679,651
| – | – |
|
16
Revolution Medicines
RVMD
$39.6B
| $48.5M | 1.07% |
1,751,496
| – | – |
|
|
17
Integra LifeSciences
IART
$1.5B
| $43M | 0.95% |
+1,126,827
| New | +$47.4M |
|
|
18
Surgery Partners
SGRY
$2.09B
| $42.7M | 0.94% |
+1,460,000
| New | +$52.5M |
|
19
ARS Pharmaceuticals
SPRY
$695M
| $41.9M | 0.92% |
11,077,927
| – | – |
|
20
Kura Oncology
KURA
$964M
| $39.9M | 0.88% |
4,374,044
+1,136,044
| +35% | +$11.5M |
|
21
Guardant Health
GH
$20.7B
| $39.4M | 0.87% |
1,329,935
+75,936
| +6% | +$2.67M |
|
|
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $38.5M | 0.85% |
2,077,893
| – | – |
|
|
SWTX
23
DELISTED
SpringWorks Therapeutics
SWTX
| $36.5M | 0.8% |
1,579,574
+225
| +0% | +$6.15K |
|
24
Cabaletta Bio
CABA
$461M
| $35.6M | 0.78% |
2,340,118
| – | – |
|
|
CMAX
25
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $33.7M | 0.74% |
529,107
+404
| +0.1% | +$28.3K |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q3 2023 Portfolio in Review
As of Q3 2023, Deerfield Management held 112 positions worth $4.54B, down 3.1% from $4.68B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Deerfield Management withdrew a net $1.24B in Q3 2023, closing 24 positions and reducing 7 holdings. Its most notable exit was Amedisys, an estimated $164M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 68% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in Bio-Rad Laboratories Class A worth $62.4M.
- Deerfield Management's largest Q3 2023 buy was Bio-Rad Laboratories Class A: 173,947 shares worth $62.4M.
- Deerfield Management added most to Centene in Q3 2023, an estimated $42.6M increase.
- Deerfield Management's biggest Q3 2023 reduction was Cogent Biosciences, cutting an estimated $27M.
- Deerfield Management fully exited Amedisys in Q3 2023, selling an estimated $164M.
- Deerfield Management's ten largest holdings make up 55% of its $4.54B portfolio in Q3 2023.
- Deerfield Management opened 14 new positions and closed 24 in Q3 2023.
- Deerfield Management's portfolio value fell 3.1% quarter-over-quarter to $4.54B.
Based on Deerfield Management's 13F filing for Q3 2023, filed 14 Nov 2023.